346 POSTER CBP501, a novel cell cycle G2 checkpoint abrogator. Preliminary results of the initial phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study in patients (pts) with advanced solid tumors
M.S. Gordon; J.P. Eder; D.S. Mendelson; E. Wasserman; W. Sutherland; T. Kawabe; G.I. Shapiro
作者M.S. Gordon; J.P. Eder; D.S. Mendelson; E. Wasserman; W. Sutherland; T. Kawabe; G.I. Shapiro